Business Wire

RYAN

Share
Ryan Acquires Qvalia’s VAT Compliance and Recovery Business in the Nordics

Ryan , a leading global tax services and software provider, today announced the acquisition of Qvalia’s value added tax (VAT) compliance and recovery business. As a major market provider of VAT services in the Nordics, this acquisition significantly expands Ryan’s brand in the region and continues to strengthen and grow its service offerings across Europe.

“Ryan’s commitment to our clients in the European region is evident by our expansion into the Nordics,” said Ryan Chairman and CEO G. Brint Ryan . “We’re thrilled to welcome Qvalia’s highly experienced tax professionals to our workplace. Our clients will benefit from Qvalia’s leading VAT recovery and compliance services in the Nordics, while Qvalia’s clients can now take advantage of Ryan’s full suite of tax services globally, creating tax centres of excellence.”

Founded in 2007, with headquarters in Stockholm, Sweden and offices in Norway, Finland, and Denmark, Qvalia has helped the region’s largest organisations analyse accounting data, manage costs, reduce risks, and improve the entire tax process. This strategic acquisition adds 32 highly qualified VAT professionals, located across four new office locations to Ryan’s European team, including Qvalia’s four senior country leaders: Michael Bernhardtsen in Denmark, Andre Klemsdal in Norway, Teemu Kamu in Finland, and Cathrine Engman in Sweden. Collectively, with more than 40 years of experience, they will focus on Ryan’s growth trajectory in their respective country markets, bringing additional value to their existing clients.

“The addition of Qvalia’s VAT compliance and recovery team further solidifies Ryan as a leading provider of VAT services in Europe. Qvalia’s innovative and transformative approach and culture are a powerful fit with our mission to help our clients transform their tax function into centers of excellence,” said Jon C. Sweet, Ryan’s President of European and Asia-Pacific Operations . “This acquisition not only positions Ryan as the preeminent VAT provider in the Nordics, but it also strengthens our VAT compliance and recovery practice throughout Europe.”

Qvalia’s finance process automation platform and fintech will continue to operate under the Qvalia name and brand and will not be included as part of the acquisition. With significant synergies existing between the two companies, there will be continued opportunities for both Qvalia’s and Ryan’s combined client base to leverage discreet offerings, as the two organisations partner prospectively.

“This is an exciting opportunity for Qvalia’s VAT compliance and recovery team to join a global leading tax firm. After founding and growing this practice over the last 15 years, I am confident this team will bring valuable in-depth knowledge, expertise, and experience of the Nordic market to Ryan,” said Henri Taipale, CEO and founder of Qvalia, who will be focusing on further growing Qvalia’s finance process automation platform. “I am looking forward to continuing to partner with Ryan and joining forces to be able to serve our mutual clients in an excellent and innovative way.”

About Ryan

Ryan, an award-winning global tax services and software provider, is the largest Firm in the world dedicated exclusively to business taxes. The Firm provides an integrated suite of international tax services on a multijurisdictional basis, including cost management, compliance, consulting, and technology services. Ryan is a nine-time recipient of the International Service Excellence Award from the Customer Service Institute of America (CSIA) for its commitment to world-class client service. Empowered by the dynamic myRyan work environment, which is widely recognised as the most innovative in the tax services industry, Ryan’s multidisciplinary team of more than 3,100 professionals and associates serves over 18,000 clients in more than 60 countries, including many of the world’s most prominent Global 5000 companies. More information about Ryan can be found at ryan.com/europe. “Ryan” and “Firm” refer to the global organisational network and may refer to one or more of the member firms of Ryan International, each of which is a separate legal entity.

About Qvalia

Qvalia redesigns finance processes. Founded in 2007, the company expanded to become the leading Nordic expert in financial data mining. Since 2017, the company has developed a platform for finance teams to automate financial processes, including e-invoicing, accounting, and analytics. The company has offices in Stockholm, Helsinki, Copenhagen, and Oslo.

Link:

ClickThru

Social Media:

https://www.facebook.com/RyanTax/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye